Prevalence and Risk Factors of Blindness Among Primary Angle Closure Glaucoma Patients in the United States: An IRIS® Registry Analysis.

Primary angle closure glaucoma angle closure blindness healthcare disparities

Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
07 Nov 2023
Historique:
received: 23 06 2023
revised: 03 11 2023
accepted: 03 11 2023
medline: 10 11 2023
pubmed: 10 11 2023
entrez: 9 11 2023
Statut: aheadofprint

Résumé

To assess the prevalence and risk factors of blindness among patients newly diagnosed with primary angle closure glaucoma (PACG) in the United States (US). Retrospective cross-sectional study. Eligible patients from the American Academy of Ophthalmology (AAO) IRIS® Registry (Intelligent Research in Sight) had newly diagnosed PACG, defined as: 1) observable during a 24-month lookback period from index date of PACG diagnosis; 2) no prior history of eye drops, laser, or cataract surgery unless preceded by a diagnosis of anatomical narrow angle (ANA); 3) no prior history of glaucoma surgery. Logistic regression models were developed to identify risk factors for any (one or both eyes) or bilateral (both eyes) blindness (visual acuity ≤ 20/200) at first diagnosis of PACG. Among 43,901 eligible patients, overall prevalence of any and bilateral blindness were 11.5% and 1.8%, respectively. Black and Hispanic patients were at higher risk of any (OR=1.42 and 1.21, respectively; p<0.001) and bilateral (OR=2.04 and 1.53, respectively; p<0.001) blindness compared to non-Hispanic White patients adjusted for ocular comorbidities. Age <50 or >80 years, male sex, Medicaid or Medicare insurance product, and Southern or Western practice region also conferred higher risk of blindness (OR>1.28; p≤0.01). Blindness affects 1 out of 9 patients with newly diagnosed PACG in the IRIS® Registry. Black and Hispanic patients and Medicaid and Medicare recipients are at significantly higher risk. These findings highlight the severe ocular morbidity among PACG patients and the need for improved disease awareness and detection methods.

Identifiants

pubmed: 37944688
pii: S0002-9394(23)00461-0
doi: 10.1016/j.ajo.2023.11.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Sona N Shah (SN)

Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles, CA.

Sarah Zhou (S)

Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles, CA.

Carina Sanvicente (C)

Harvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AK.

Bruce Burkemper (B)

Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles, CA.

Galo Apolo (G)

Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles, CA.

Charles Li (C)

American Academy of Ophthalmology, San Francisco, CA.

Siying Li (S)

American Academy of Ophthalmology, San Francisco, CA.

Lynn Liu (L)

American Academy of Ophthalmology, San Francisco, CA.

Flora Lum (F)

American Academy of Ophthalmology, San Francisco, CA.

Sasan Moghimi (S)

Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, La Jolla, CA.

Benjamin Xu (B)

Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles, CA. Electronic address: benjamin.xu@med.usc.edu.

Classifications MeSH